U.S. Markets closed

Matinas BioPharma Holdings, Inc. (MTNB)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.8000+0.0433 (+5.72%)
At close: 04:00PM EDT
0.7900 -0.01 (-1.25%)
After hours: 07:49PM EDT

Matinas BioPharma Holdings, Inc.

1545 Route 206 South
Suite 302
Bedminster, NJ 07921
United States
908 484 8805

Full Time Employees31

Key Executives

NameTitlePayExercisedYear Born
Mr. Jerome D. Jabbour J.D.Co-Founder, CEO, Pres & Director795kN/A1974
Dr. Theresa Matkovits Ph.D.Chief Devel. Officer525.52kN/A1967
Dr. James J. Ferguson FACC, M.D.Chief Medical Officer586.3kN/A1955
Mr. Keith A. Kucinski CPA, M.B.A.Chief Financial OfficerN/AN/A1970
Dr. Hui Liu M.B.A., Ph.D.Chief Technology OfficerN/AN/A1968
Dr. Raphael J. Mannino Ph.D.Chief Scientific OfficerN/AN/A1947
Mr. Frank CalamusaExec. Director and Head of Manufacturing & Supply ChainN/AN/AN/A
Mr. Thomas J. Hoover M.B.A.Chief Bus. OfficerN/AN/A1970
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

Corporate Governance

Matinas BioPharma Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.